Conditioned medium of lipopolysaccharide-treated embryonic stem cell-derived mesenchymal stem cells modulates in vitro secretion of inflammatory cytokines

Abstract

Background: The immunomodulatory properties of mesenchymal stem cells (MSCs) secretome have been considered by many investigators, and several preconditioning strategies such as pharmaceutical preconditioning have shown to strengthen the immunomodulatory outcomes of MSCs. Objectives: Current research aimed to scrutinize the release of some main inflammatory related cytokines in peripheral blood mononuclear cells (PBMCs) induced by lipopolysaccharide (LPS), following the treatment with secretome of LPS-preconditioned human embryonic stem cell-derived MSCs (hESC-MSCs). Materials and Methods: First, hESC-MSCs were cultivated and characterized, then they were preconditioned with 1 µg/mL of LPS. The conditioned medium was collected and concentrated 15-folds. In the next step, PBMCs were separated from human peripheral blood and processed by concentrated LPS-preconditioned hESC-MSC secretome. Subsequently, PBMCs were induced by 1 µg/mL of LPS. Finally, the secreted amounts of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-10 were investigated through ELISA assay. Results: LPS-preconditioned hESC-MSC secretome considerably enhanced the secretion of IL-10 and IL-1β in PBMCs (P > 0.0001). The change of secreted level in TNF-α was not significant. Conclusion: The results implied that LPS could support the immunomodulatory outcomes of hESC-MSC secretome.